Trial Profile

A randomized, double-blind, parallel group placebo-controlled study of the safety and reduction of signs and symptoms during treatment with tocilizumab (TCZ) [Actemra; Roche] versus placebo in patients with ankylosing spondylitis who have had an inadequate response to previous TNF [tumour necrosis factor] antagonist therapy

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 03 Aug 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

31 Jul 2022 This trial has been completed in Spain (End Date: 28 Dec 2011), according to European Clinical Trials Database record.
13 Jun 2013 Results published in the Annals of the Rheumatic Diseases.
08 Apr 2013 New source identified and integrated (Clinical Trials Registry - India: CTRI2011-04-001692).

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com